Verrica
West Chester, United States · Biotechnology, Healthcare, Health Care · 78 employees
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and
Funding history
- Venture - Series Unknown — $50.0M — Dec 2025
- Venture - Series Unknown — $20.0M — Feb 2018
- Venture - Series Unknown — $5.0M — Dec 2017
- Venture - Series Unknown — $2.4M — Dec 2015
Recent signals
- Feb 12, 2026: Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
- Dec 10, 2025: Raised $50.0M in Venture - Series Unknown
- Nov 23, 2025: SEC 8-K (1.01): On November 23, 2025, Verrica Pharmaceuticals, Inc. entered into two Securities Purchase Agreements to conduct a private placement transaction with institutional and accredited investors. The Company agreed to sell approximately 6.5 million shares of common stock along with pre-funded warrants for approximately 5.3 million shares and Series C warrants for around 2.9 million shares. This financing is intended to support the Company's ongoing operations and strategic initiatives. The move is significant as it provides the necessary capital for future growth, while also involving a considerable number of convertible instruments that could affect the Company's share structure.
- Mar 26, 2025: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
- Feb 21, 2018: Raised $20.0M in Venture - Series Unknown
- Dec 22, 2017: Raised $5.0M in Venture - Series Unknown
- Dec 17, 2015: Raised $2.4M in Venture - Series Unknown
See plans & pricing → Track Verrica’s funding, hiring, and signals — with verified contacts — on Fundz.